Paul Perreault
-
Boathouse Row to Light Up for Rare Disease Day, Says King of Prussia’s CSL Behring CEO
“Our collective hope shines a light on the progress made and challenges ahead,” CSL Behring Limited CEO and Managing Director Paul…
-
King of Prussia’s CSL Behring to Acquire Calimmune for $91M
King of Prussia’s biotherapeutics company CSL Behring is acquiring Calimmune, a clinical-stage biotechnology company, for $91 million, writes Linda Loyd…
-
CEO of King of Prussia’s CSL Ltd. Discusses Impact of Gene Therapy
Paul Perreault, the 59-year-old chief executive officer and managing director of CSL Ltd., recently discussed with the Philadelphia Inquirer the…
Founding Partners
Advertisement
Affiliate Partners
Community Partners
